Last reviewed · How we verify
NCT03246113
Tolerability of Cannabis in Patients Receiving Concurrent Chemoradiation for Glioblastoma
Phase 1 trial testing Cannabis in Glioblastoma in 1 participant. Terminated before completion.
9 May 2019
Quick facts
| Lead sponsor | New York State Psychiatric Institute |
|---|---|
| Phase | Phase 1 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 1 |
| Start date | 19 March 2018 |
| Primary completion | 9 May 2019 |
| Estimated completion | 9 May 2019 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Cannabis — full drug profile →
- Temozolomide (temozolomide) — full drug profile →
- Radiation Therapy — full drug profile →
Conditions studied
- Glioblastoma — all drugs for Glioblastoma →
Sponsor
New York State Psychiatric Institute
Who can join
Adults 21 to 70, any sex, with Glioblastoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this single arm Phase I feasibility study is to investigate the tolerability of cannabis with concurrent chemoradiation in the treatment of glioblastoma multiforme (GBM). A strain of cannabis provided by The National Institute of Drug Abuse (NIDA) that has a high concentration of cannabidiol (CBD) and a low concentration of THC (relative to average street cannabis) will be tested in order to maximize clinical efficacy while minimizing intoxicating side effects in this medically-ill population.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
Cannabinoids in the landscape of cancer.
Mangal N, Erridge S, Habib N, Sadanandam A, et al · · 2021 · cited 72× · PMID 34259916 · DOI 10.1007/s00432-021-03710-7 -
Overcoming Glucocorticoid Resistance in Acute Lymphoblastic Leukemia: Repurposed Drugs Can Improve the Protocol.
Olivas-Aguirre M, Torres-López L, Pottosin I, Dobrovinskaya O. · · 2021 · cited 34× · PMID 33777761 · DOI 10.3389/fonc.2021.617937 -
Targeting the Sphingolipid Rheostat in Gliomas.
Zaibaq F, Dowdy T, Larion M. · · 2022 · cited 24× · PMID 36012521 · DOI 10.3390/ijms23169255 -
New Avenues and Major Achievements in Phytocompounds Research for Glioblastoma Therapy.
Majchrzak-Celińska A, Studzińska-Sroka E. · · 2024 · cited 8× · PMID 38611962 · DOI 10.3390/molecules29071682 -
From bench to bedside: the application of cannabidiol in glioma.
Feng S, Pan Y, Lu P, Li N, et al · · 2024 · cited 7× · PMID 38987805 · DOI 10.1186/s12967-024-05477-0 -
The Anti-Glioblastoma Effects of Novel Liposomal Formulations Loaded with Cannabidiol, Celecoxib, and 2,5-Dimethylcelecoxib.
Rybarczyk A, Majchrzak-Celińska A, Piwowarczyk L, Krajka-Kuźniak V. · · 2025 · cited 3× · PMID 40871052 · DOI 10.3390/pharmaceutics17081031
Verify or expand the search:
- PubMed search for NCT03246113
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Cannabis
Trials testing the same drug.
- NCT06137365 — Cannabis for Obesity Trial · Phase 2 · not yet recruiting
- NCT03734731 — Cannabis Vs Opioids Pain Management Objective Testing Comparisons · NA · not yet recruiting
- NCT05563948 — Repeated Administration of Cannabis Varying in THC and CBD · Phase 2 · suspended
- NCT06351540 — Examining the Role of Tolerance on Dose-dependent Effects of Acute THC on Oculomotor and Cognitive Performance · Phase 1 · not yet recruiting
- NCT07216690 — Pregnenolone as a Treatment for Cannabis Intoxication · Phase 2 · recruiting
Other recruiting trials for Glioblastoma
Currently open trials in the same condition.
- NCT07284069 — Senicapoc and Perampanel for Newly Diagnosed Glioblastoma · EARLY_PHASE1 · recruiting
- NCT05653635 — Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study · Phase 2 · recruiting
- NCT07480941 — Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma · Phase 1 · recruiting
- NCT07448480 — Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas · active not recruiting
- NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
Other New York State Psychiatric Institute trials
Trials by the same sponsor.
- NCT05416658 — Shared Decision Making for Antipsychotic Medications · NA · not yet recruiting
- NCT07423546 — A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia · Phase 1, PHASE2 · not yet recruiting
- NCT05339256 — Sublingual Buprenorphine Through Telemedicine vs In-Person Care as Usual · Phase 2 · not yet recruiting
- NCT05563948 — Repeated Administration of Cannabis Varying in THC and CBD · Phase 2 · suspended
- NCT06977308 — A Multimodal Imaging Study of Dopamine in Early Psychosis · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03246113 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by New York State Psychiatric Institute
- Last refreshed: 13 August 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03246113.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing